Overview
Dr. Stephan Rau focuses his practice on mergers and acquisitions (M&A) transactions and regulatory advice in the health and life science sector. He is the head of the Firm’s Health Law Practice Group in Europe.
In 2004, Stephan was adviser on the foundation of the first German corporate medical center. Since then he has represented numerous investors, health care service providers, pharmaceutical and medtech companies, as well as governmental entities in M&A transactions, outsourcing projects, and licensing and reimbursement proceedings.
Stephan speaks regularly at health care and life sciences industry as well as legal expert conferences, both at an international and national level. He is the author of numerous publications on German corporate law, health care and life sciences regulation.
For many years Stephan has consistently been ranked Tier 1 attorney for Health in Germany by Chambers Europe and “Elite Leading Lawyer” for Health and Life Sciences by Legal 500 Germany. JUVE lists Stephan as a frequently recommended lawyer for Corporate, M&A and Private Equity and a leading advisor for health. LMG Life Sciences Europe has repeatedly listed Stephan as a “Life Sciences Star” for his outstanding work in the industry.
Results
- Advising on investments in the clinical lab, renal care, hospital, pharma, medical device, biotech, food and online pharmacy businesses
- Structuring various outsourcing projects, such as joint ventures between one of the largest medical schools in Europe and a large public hospital carrier leading to the establishment of the largest European clinical lab
- Challenging market entry barriers to dialysis service providers under the German system of determination of need of the statutory health insurance system
- Advising on disease management agreements with statutory health insurance funds
- Challenging one of the largest public tenders for pharmaceuticals by the largest German public payer
- Providing advice in connection with compulsory early benefit assessments for new pharmaceutical products and related price negotiations under the Pharmaceuticals Market Reorganization Act (Arzneimittelmarkt-Neuordnungsgesetz (AMNOG)) proceedings
Recognitions
- The Best Lawyers in Germany 2021, ‘Lawyer of the Year’ in Pharmaceuticals Law
- Expert Guides; Best of the Best 2019: Regulatory, Finance & Transactional, Germany
- Handelsblatt/Best Lawyers™ 2022 Germany: Leading Lawyer for Mergers and Acquisitions Law and Pharmaceuticals Law,
- Leaders League’s 2019 guide, Innovation, Technology & Patents, “Excellent” in the Health, pharma & biotechnology category
- The Best Lawyers in Germany 2019, Mergers & Acquisitions
- Chambers Europe 2021, Leading Individual, Band 1 for Healthcare in Germany
- Expert Guides; Best of the Best 2018: Regulatory, Financing & Transactional, Germany
- Who’s Who Legal: Healthcare 2021
- JUVE Handbook, frequently recommended lawyer for Corporate, M&A and Private Equity, and distinguished advisor for Health Services
- Who’s Who Legal: Life Sciences 2021
- The Legal 500 EMEA 2021, Leading Individual for Healthcare and Life Sciences
- The Legal 500 2017, Recommended Individual for Corporate M&A
- LMG Life Sciences, Life Science Star
Community
Credentials
Education
Humboldt University of Berlin, Dr. jur. (PhD), 2003
Higher Court of Appeal, Berlin, Second State Exam, 1998
University of Heidelberg, First State Exam, 1996
University of Paris-Dauphine, Maîtrise en Économie Appliquée, 1994
London School of Economics and Political Science, Master of Science in Government, 1993
IHK Wiesbaden, interpreter and translator for Russian, 1990
Admissions
Germany
Courts / Agencies
All Courts and Courts of Appeal in Germany
Languages
English
German
French
Russian
